SAN
JOSE, Calif., May 21, 2024
/PRNewswire/ -- Vantis Vascular, Inc. (Vantis), a pioneering
medical technology company founded by physicians with a passion to
revolutionize vascular interventions, announced today the
successful closing of a $5 million
SAFE (Simple Agreement for Future Equity) financing round, which is
convertible upon Vantis' future Series C preferred round. This
financing, which follows a total raise of $24 million to date from high-net-worth
individuals and NIH grants, marks a significant milestone in
Vantis' journey to advance the field of interventional cardiology
and improve patient outcomes.
Funds will accelerate development
efforts, while supporting the near-term commercial launch of our
CrossFAST™ system.
"At Vantis, we're on a mission to transform the way the medical
community navigates and treats complex and calcific arteries," said
Jason Turner, Chief Executive
Officer at Vantis. "This financing underscores the confidence of
our investors in our vision, experienced management team, and the
potential of our technologies to drive innovation and make a
lasting impact in vascular interventions. This round will aid to
accelerate our development efforts, while supporting the near-term
commercial launch of our CrossFAST system."
Vantis' flagship products in development include the CrossFAST™
Integrated Microcatheter Guide Extension System and the CrossSHOCK™
Intravascular Lithotripsy (IVL) System. These innovative,
next-generation solutions aim to enhance the delivery, safety and
efficacy of vascular interventions, ultimately improving patient
outcomes and quality of life.
"Coronary interventions are becoming increasingly more
challenging, requiring specialized tools to deliver lifesaving
therapies," stated Tim Fischell, MD,
Chief Medical Officer at Vantis. "We are excited about the
potential of our purpose-built, next-generation products to address
these critical challenges. Physicians express a significant need to
improve existing catheter-based technologies given anatomical
challenges and the fact that we are treating more complex cases.
Providing an integrated catheter system that will enhance
procedural efficiency from start to finish will be
game-changing."
The CrossFAST Integrated Microcatheter Guide Extension System,
with 2-in-1 DuoPro™ Interlocking Technology, provides
interventionalists with enhanced control and maneuverability to
traverse the most calcific and tortuous anatomies, while the
CrossSHOCK IVL System utilizes a low profile, micro electrode
design to optimize the IVL experience, while striving for a safer,
faster and more efficient approach to treating calcified arteries.
Both products serve large and growing cardiovascular markets,
including the multibillion IVL opportunity.
Products are currently in development and are not commercially
available for sale in any geography. For more information about
Vantis and its groundbreaking technology, visit
www.vantisascular.com.
About Vantis Vascular:
Vantis Vascular, Inc. is a medical technology company dedicated
to revolutionizing vascular interventions. Founded by physicians,
Vantis develops performance-driven technologies that aim to provide
faster, safer and more effective treatments to patients. With a
focus on innovation and patient-centric solutions, Vantis is
committed to advancing the field of interventional cardiology and
improving patient outcomes worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/vantis-vascular-secures-5-million-in-safe-financing-to-drive-innovation-in-vascular-interventions-302150782.html
SOURCE Vantis Vascular, Inc.